Park Vale Capital is an alternative investment firm dedicated to managing assets on behalf of institutions and foundation.
Park Vale Capital is an investment firm that is dedicated to developing and managing fiduciary long term capital in a number of specific, unusual and focused investment strategies.Park Vale advice and provide high-value investment products through direct deal opportunities, funds, and tailor-made investment solutions. Park Vale is built on the pursuit of unusual (low correlation to traditional assets), risk-adjusted positive performance which is designed to drive meaningful out performance in the total asset allocation.Park Vale operate from offices in London, New York, Hong Kong and Shanghai to ensure we are able to source and manage our networks, information and deal flow.Park Vale and it’s partners are experienced professionals with expertise in private equity, Biotechnology, China Special Situations, Real Estate Opportunities, Adaptive Strategies, New Technology, Global Energy, and JABCAP (LUX).
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 3, 2017
Cullinan Oncology
|
Series A | $150M | Biopharma | — |
Jan 7, 2016
Dearman technologies
|
Series Unknown | £16M | CleanTech | Yes |
Aug 25, 2015
Causemo
|
Series A | $4M | Big Data | — |
Park Vale Capital has had 2 exits. Park Vale Capital most notable exits include Cullinan Oncology , Causemo
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jan 7, 2021 | Cullinan Oncology | IPO | Biopharma | Detail |
Aug 14, 2019 | Causemo | M&A | Big Data | Detail |